SOLIFENACIN

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H26N2O2
Molecular Weight	362.4647
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of SOLIFENACIN

Structure Search

SMILES

O=C(O[C@H]1CN2CCC1CC2)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5

InChI

InChIKey=FBOUYBDGKBSUES-VXKWHMMOSA-N

InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C23H26N2O2
Molecular Weight	362.4647
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:26:35 UTC 2023` Edited by `admin` on `Fri Dec 15 16:26:35 UTC 2023`
Record UNII	A8910SQJ1U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SOLIFENACIN

Official Name

English

solifenacin [INN]

Common Name

English

NSC-759144

Code

English

SOLIFENACIN [MI]

Common Name

English

Solifenacin [WHO-DD]

Common Name

English

SOLIFENACIN [VANDF]

Common Name

English

Classification Tree Code System Code

WHO-ATC

G04CA53

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

NDF-RT

N0000000125

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

WHO-ATC

G04BD08

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

NDF-RT

N0000000125

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

WHO-VATC

QG04CA53

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

LIVERTOX

NBK548716

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

NDF-RT

N0000000125

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

WHO-VATC

QG04BD08

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

NCI_THESAURUS

C29704

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

NDF-RT

N0000175700

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

Code System Code Type Description

RXCUI

322167

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

MESH

C441209

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

LACTMED

Solifenacin

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

MERCK INDEX

m10108

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

Merck Index

INN

8155

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

DRUG CENTRAL

2457

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

DRUG BANK

DB01591

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

SMS_ID

100000084906

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

EVMPD

SUB21589

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

EPA CompTox

DTXSID3048289

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

CAS

242478-37-1

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

IUPHAR

7483

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

ChEMBL

CHEMBL1734

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

NSC

759144

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

DAILYMED

A8910SQJ1U

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

NCI_THESAURUS

C75284

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

FDA UNII

A8910SQJ1U

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

PUBCHEM

154059

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

WIKIPEDIA

SOLIFENACIN

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

PRIMARY

RXCUI

477364

Created by admin on Fri Dec 15 16:26:35 UTC 2023 , Edited by admin on Fri Dec 15 16:26:35 UTC 2023

ALTERNATIVE

Related Record Type Details


					W3JX5KZ4V2

MUSCARINIC ACETYLCHOLINE RECEPTOR M3

TARGET -> INHIBITOR

Comments:

Appears to be more bladder-selective for the M3 receptor relative to salivary glands.eptor

Qualification:

Ki

Amount:


					25HF7HWP9L

Solifenacin fumarate

SALT/SOLVATE -> PARENT

Amount:


					081I12ZA58

CYTOCHROME P450 2C19

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MINOR


					U87RX375T5

MUSCARINIC ACETYLCHOLINE RECEPTOR M2

TARGET->WEAK INHIBITOR

Qualification:

Ki

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Comments:

in vivo

Interaction Type:

BINDING

Amount:


					A8910SQJ1U

EXCRETED UNCHANGED

Qualification:

URINE

Amount:


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MAJOR


					KKA5DLD701

SOLIFENACIN SUCCINATE

SALT/SOLVATE -> PARENT


					CCM244AP8R

SOLIFENACIN TARTRATE

SALT/SOLVATE -> PARENT


					V23K99CV7G

MUSCARINIC ACETYLCHOLINE RECEPTOR M1

TARGET -> INHIBITOR

Qualification:

Ki

Amount:

Related Record Type Details


					67V0THE6SU

SOLIFENACIN N1-OXIDE

METABOLITE INACTIVE -> PARENT

Comments:

major in urine

Interaction Type:

MAJOR

Qualification:

PLASMA; URINE


					JZ88528ZLX

4R-HYDROXY SOLIFENACIN N1-OXIDE

METABOLITE ACTIVE -> PARENT

Comments:

major in urine

Interaction Type:

MAJOR

Qualification:

PLASMA; URINE


					SLB9733RQR

SOLIFENACIN N1-GLUCURONIDE

METABOLITE INACTIVE -> PARENT

Interaction Type:

MINOR

Qualification:

PLASMA


					C6W0J0Z253

4-HYDROXY SOLIFENACIN, (4R)-

METABOLITE ACTIVE -> PARENT

Comments:

occurs at low concentrations and unlikely to contribute significantly to clinical activity

Interaction Type:

MINOR

Qualification:

PLASMA


					C6W0J0Z253

4-HYDROXY SOLIFENACIN, (4R)-

METABOLITE ACTIVE -> PARENT

Interaction Type:

MAJOR

Qualification:

URINE


					C6W0J0Z253

4-HYDROXY SOLIFENACIN, (4R)-

METABOLITE ACTIVE -> PARENT

Qualification:

FECAL

Related Record Type Details


					A8910SQJ1U

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Volume of Distribution	PHARMACOKINETIC

Tmax	PHARMACOKINETIC				ORAL ADMINISTRATION AT STEADY-STATE

Biological Half-life	PHARMACOKINETIC